Publication: Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: A randomized, double-blind, placebo-controlled study
Issued Date
2005-01-01
Resource Type
ISSN
09575235
Other identifier(s)
2-s2.0-27844454825
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Blood Coagulation and Fibrinolysis. Vol.16, No.8 (2005), 549-555
Suggested Citation
Ampaiwan Chuansumrit, Somporn Wangruangsatid, Yujinda Lektrakul, Mary Ng Chua, Maria Rosario Zeta Capeding, Ole Molskov Bech Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: A randomized, double-blind, placebo-controlled study. Blood Coagulation and Fibrinolysis. Vol.16, No.8 (2005), 549-555. doi:10.1097/01.mbc.0000186837.78432.2f Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/17140
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: A randomized, double-blind, placebo-controlled study
Abstract
Objectives: We evaluated the efficacy and safety of recombinant activated factor VII (rFVIIa) in children aged < 18 years old with grade II or grade III Dengue hemorrhagic fever (DHF) who required blood component therapy for controlling bleeding episodes. Study design: Patients were randomized to the rFVIIa group or placebo group in a ratio of 2:1. rFVIIa or placebo (100 μg/kg body weight) was given by intravenous bolus injection. When bleeding was not effectively controlled, a second dose of rFVIIa or placebo (100 μg/kg) was given 30 min after the first dose. Results: Nine and 16 patients received placebo and rFVIIa, respectively. The demographics, bleeding manifestations and grade of DHF were similar for the rFVIIa and placebo groups. Apart from petechiae and ecchymosis, one to four additional bleeding sites were found in each patient, including hematemesis (n = 15), epistaxis (n = 14), gum bleeding (n = 12), melena (n = 7), hypermenorrhea (n = 4), hematochezia (n = 2) and hematuria (n = 2). The mean total dose of rFVIIa (138.4 ± 50.9 μg/kg) and placebo (145.4 ± 53.7 μg/kg) were comparable. The efficacy of bleeding control at 2 h after the first dose was completely ceased (rFVIIa 75.0% versus placebo 44.4%), decreased (rFVIIa 18.7% versus placebo 11.2%), and unchanged or worsened (rFVIIa 6.3% versus placebo 44.4%). Some patients with active bleeding received platelet concentrates 3-12 h after the first dose of rFVIIa or placebo. The subsequent efficacy of bleeding control at 6, 12 and 24 h was comparable between the two groups. The cumulative use of red blood cells (rFVIIa 31.3% versus placebo 33.3%) and plasma (rFVIIa 25% versus placebo 22%) during the 24-h period was not significantly different between the two groups. In contrast, platelet concentrate requirement in the rFVIIa group (6.3%) was lower than the placebo (33.3%). No clinical evidence of thromboembolic complications or mortality as a result of bleeding was observed. Conclusion: rFVIIa appears to be a useful adjunctive treatment to blood component transfusion for controlling active bleeding in children with DHF especially when platelet concentrate is not readily available. © 2005 Lippincott Williams & Wilkins.